On Thursday, in the course of Afternoon trade, Shares of Novatel Wireless Inc (NASDAQ:MIFI), dropped -2.84%, and is now trading at $3.08.
Novatel Wireless Inc, declared AT&T (NYSE:T) network approval of the MiFi(R) Secure SA 1100, the first offering in a new platform designed specifically for the control and automation market. The SA 1100 series presents customers with opportunities to create differentiated services that drive business growth. Out of the gate, the portfolio has made its introduction into the home security solutions market, a segment within the control and automation market.
The SA 1100, declared in April with Icontrol Networks at the ISC West Conference, is a dual path communicator board for independent security dealers to easily install in home security panels. The solution empowers home security alarm providers to expedite the current 3G cellular upgrade requirement for pre-installed security devices on the AT&T network in addition to offering home automation services by simplifying communication of smart home appliances through one touch point via Wi-Fi and Z-Wave(R) protocols. The portfolio comprises open standards-based products with the ability to run “as-a-service” solutions that enable providers to enter new markets and grow revenue.
Novatel Wireless, Inc. provides wireless broadband access solutions for the mobile communications market worldwide. It operates in the Mobile Computing Products, and M2M Products and Solutions segments.
During an Afternoon trade, Shares of VCA Incm (NASDAQ:WOOF), dipped -1.23%, and is now trading at $53.94.
VCA Incm, will report financial results for its second quarter of 2015 on Wednesday, July 29th, 2015, at 8:00 a.m. ET. The company will host a conference call and webcast startning at 9:00 a.m. ET on that day.
The webcast can be accessed by visiting the company’s website at http://investor.vca.com. Replay of the webcast will be accessible for ninety days by visiting the company’s website.
VCA Inc. operates as an animal healthcare company in the United States and Canada. It operates through two segments, Animal Hospital and Laboratory. The Animal Hospital segment offers general medical and surgical services, in addition to specialized treatments comprising advanced diagnostic services, internal medicine, oncology, neurology, endocrinology, ophthalmology, dermatology, and cardiology for companion animals; and sells related retail and pharmaceutical products.
Shares of Star Bulk Carriers Corp. (NASDAQ:SBLK), during its Thursday’s current trading session fell -55.80%, and is now trading at $14.58.
Star Bulk Carriers Corp., declared its unaudited financial and operating results for the first quarter ended March 31, 2015.
Star Bulk Carriers Corp., a shipping company, provides seaborne transportation solutions in the dry bulk sector worldwide. Its vessels transport various bulks, which comprise iron ore, coal, and grain, in addition to bauxite, fertilizers, and steel products. As of April 21, 2015, the company owned 70 dry bulk vessels, counting 1 Newcastlemax, 19 Capesize, 4 Post-Panamax, 20 Kamsarmax, 8 Panamax, 7 Ultramax, 10 Supramax, and 1 Handymax vessel with a total carrying capacity of 7.2 million dwt. It also provides vessel administration services to dry bulk vessels. Star Bulk Carriers Corp. is based in Athens, Greece.
Finally, Incyte Corporation (NASDAQ:INCY), gained 0.93% to $105.42.
Incyte Corporation, declared that five abstracts featuring data from three clinical studies and separate pharmacology studies for its investigational rheumatoid arthritis drug baricitinib will be presented at the 2015 annual meeting of the European League Against Rheumatism in Rome June 10-13. Lilly and Incyte formerly released positive topline results for the RA-BEACON and RA-BUILD studies, both of which met their primary endpoint of ACR20 at 12 weeks as contrast to placebo.
“Incyte is committed to translating R&D excellence into new medicines, and we are very happy with the initial results from the Phase 3 trials program of baricitinib,” said Rich Levy, M.D., chief drug development officer at Incyte Corporation.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
